Baxter International Inc. (BAX)
| Market Cap | 9.27B |
| Revenue (ttm) | 11.24B |
| Net Income (ttm) | -957.00M |
| Shares Out | 516.25M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | 9.42 |
| Dividend | $0.04 (0.22%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 9,652,417 |
| Open | 18.55 |
| Previous Close | 18.49 |
| Day's Range | 17.94 - 18.61 |
| 52-Week Range | 15.73 - 32.68 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 21.00 (+16.96%) |
| Earnings Date | Apr 30, 2026 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $21.0, which is an increase of 16.96% from the latest price.
News
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolio...
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, A...
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solutio...
Baxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, ...
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.
EU regulator warns of shortage in Baxter's cancer treatment until early 2027
The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next ...
Baxter Announces CFO Transition
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade....
Baxter International Transcript: Barclays 28th Annual Global Healthcare Conference
Middle East exposure is minimal and oil price sensitivity has dropped by over half since 2022, mainly due to business divestitures and delivery model changes. New leadership and operating models are driving efficiency, while Advanced Surgery and HST show strong performance. Margin recovery is expected in the second half of the year.
Baxter International Transcript: Citi’s 2026 Unplugged MedTech and Life Sciences Access Day
Medtech fundamentals are stable, with new leadership driving operational consistency and innovation. Guidance for 2026 is prudent, reflecting a new baseline in IV solutions, ongoing Novum pump ship hold, and a focus on deleveraging and margin improvement.
Baxter Shares Tank As 2026 Profit Guidance Falls Below Expectations
Baxter reported a fourth-quarter adjusted EPS of 44 cents, below the management guidance of 52-57 cents and the Wall Street estimate of 54 cents. The decrease was driven primarily by an unfavorable pr...
Baxter International Earnings Call Transcript: Q4 2025
Fourth quarter sales grew 8% reported, but margins and EPS were pressured by mix, costs, and non-recurring items. 2026 guidance calls for flat to 1% sales growth and EPS of $1.85–$2.05, with improvement expected in the second half.
Baxter forecast 2026 profit below estimates
Medical products maker Baxter forecast annual profit below Wall Street estimates on Thursday, due to persistent impact from hurricane-related disruptions at a key manufacturing unit.
Baxter Reports Fourth-Quarter 2025 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. “While we delivered sales growth across all segm...
Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, ...
Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings
DEERFIELD, Ill.--(BUSINESS WIRE)--BAXTER INTRODUCES THE DYNAMO SERIES, A NEW SMART STRETCHER TO HELP ADDRESS COMMON CHALLENGES IN HOSPITAL SETTINGS.
Baxter International Transcript: 44th Annual J.P. Morgan Healthcare Conference
A new CEO is driving operational excellence, innovation, and a culture of continuous improvement, with a focus on stabilizing the business, reducing leverage, and launching new products. Financial discipline and decentralized decision-making are central, while product and process innovation remain top priorities.
MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges
CHARLESTON, S.C.--(BUSINESS WIRE)--MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-qua...
Baxter to Present at J.P. Morgan 2026 Healthcare Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, B...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Baxter International and Molina Healthcare on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Baxter International, Inc....
DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter's Brain at the American Film Market Pitch Conference
LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Dr. Walter Jacobson, a Los Angeles-based psychiatrist, author, and first-time filmmaker, scored a major win at this year's American Film Market (AFM) Pit...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas ...
BAX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Baxter to Contact Him Directly to Discuss Their Options If you purchased or acquired ...
Bragar Eagel & Squire, P.C. Reminds James Hardie and Baxter International Investors to Contact the Firm Regarding Their Rights
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stoc...